【Product for Licensing】High Binding Affinities and Potent Anti-tumor Efficacy Nectin4-CD137 BsAb

Project ID：BP-20240318-OR-029

Product Brief Summary

• Product Name: High Binding Affinities and Potent Anti-tumor Efficacy Nectin4-CD137 BsAb
• Modality: Bispecific Antibody
• Target: Nectin4 x CD137
• Therapeutic Area: Oncology
• Current Stage: Ready for IND enabling
• Rights Available: China/Global Right
• Collaboration Mode: License out / co-development

Key Advantages:

• Nectin-4 has low-level expression in some normal tissues. Nectin4 ADC and PDC have therapeutic limitations due to hepatoxicity, skin toxicity and other toxicities
• By leveraging the company’s next generation-CD137 BsAb platform, a Nectin4-CD137 BsAb was designed and built to localize CD137-mediated tumor cell killing.

It demonstrated potent anti-tumor activities in vitro and in vivo.

• The BsAb shows high binding affinities to human Nectin4 and CD137 on the Cells
• The BsAb Activates CD137 Signaling Pathway in TAA Dependent Manner
• The BsAb Induces TDCC to Kill T47D cells
• The BsAb Demonstrates Potent Anti-tumor Efficacy on MC38-hNectin4 tumor

Notes: T47D is a human breast cancer cell line endogenously expressing nectin4

The BsAb exhibits good purity after 1-step ProtA purification

• Both BsAbs (transiently expressed) show >97% main peak on analytic SEC after 1step Protein A purification
• No significant aggregations after 5x freeze-thaw

Contact

• If interested, please contact DrugTimes BD Team at BD@drugtimes.cn. Many thanks!